Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)

Full Show: Best of Bloomberg West (07/22)
49:29 - The best interviews and technology news highlights from the week are brought together in Best of Bloomberg West, a weekly long-form program, hosted by Bloomberg West's Emily Chang. (Source: Bloomberg)
  • Full Show: Bloomberg Businessweek (07/22)
  • How Yahoo Assets Could Fit Into Verizon
  • What to Expect From Apple's Third-Quarter Earnings Report